How to buy Werewolf Therapeutics stock (Werewolf Therapeutics)

Werewolf Therapeutics is a biotechnology business based in the US. Werewolf Therapeutics shares (HOWL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.55 – a decrease of 2.52% over the previous week. Werewolf Therapeutics employs 45 staff and has a trailing 12-month revenue of around $3.4 million.

Our top picks for where to buy Werewolf Therapeutics stock

Buy Werewolf Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Werewolf Therapeutics stock price (NASDAQ: HOWL)

Use our graph to track the performance of HOWL stocks over time.

Werewolf Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.55
52-week range	$1.38 - $8.19
50-day moving average more info button	$2.10
200-day moving average more info button	$3.26
Wall St. target price	$12.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.52

Is it a good time to buy Werewolf Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Werewolf Therapeutics price performance over time

Historical closes compared with the close of $1.59 from 2024-12-26

1 week (2024-12-20)	1.59
1 month (2024-11-27)	-19.29%
3 months (2024-09-27)	-25.00%
6 months (2024-06-28)	-34.84%

1 year (2023-12-28)	-61.69%
2 years (2022-12-28)	-12.64%
3 years (2021-12-28)	11.61
5 years (2019-12-24)	N/A

Werewolf Therapeutics financials

Revenue TTM	$3.4 million
Gross profit TTM	$-37,360,000
Return on assets TTM	-26.16%
Return on equity TTM	-61.56%
Profit margin	0%
Book value	$2.04
Market Capitalization more info button	$68.6 million

TTM: trailing 12 months

Werewolf Therapeutics share dividends

We're not expecting Werewolf Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Werewolf Therapeutics share price volatility

Over the last 12 months, Werewolf Therapeutics's shares have ranged in value from as little as $1.38 up to $8.1939. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Werewolf Therapeutics's is 0.414. This would suggest that Werewolf Therapeutics's shares are less volatile than average (for this exchange).

To put Werewolf Therapeutics's beta into context you can compare it against those of similar companies.

• Curis (CRIS.US): 3.349
• Applied Therapeutics (APLT.US): 2.018
• AVEO Pharmaceuticals (AVEO.US): 0.977

Werewolf Therapeutics overview

Werewolf Therapeutics, Inc. , a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

What percentage of Werewolf Therapeutics is owned by insiders or institutions?
Currently 6.112% of Werewolf Therapeutics shares are held by insiders and 72.623% by institutions. How many people work for Werewolf Therapeutics?
Latest data suggests 45 work at Werewolf Therapeutics. When does the fiscal year end for Werewolf Therapeutics?
Werewolf Therapeutics's fiscal year ends in December. Where is Werewolf Therapeutics based?
Werewolf Therapeutics's address is: 200 Talcott Ave, Watertown, MA, United States, 02472 What is Werewolf Therapeutics's ISIN number?
Werewolf Therapeutics's international securities identification number is: US95075A1079